Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial.

J Infect

Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd, Beijing, China; Cell Culture Engineering Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Electronic address:

Published: February 2023

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672836	PMC
http://dx.doi.org/10.1016/j.jinf.2022.11.008	DOI Listing

Publication Analysis

safety immunogenicity

immunogenicity bivalent

bivalent sars-cov-2

sars-cov-2 recombinant

recombinant protein

protein vaccine

vaccine sctv01c

sctv01c unvaccinated

unvaccinated adults

adults randomized

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!